{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:08:01Z","timestamp":1792271281607,"version":"4.4.0"},"reference-count":66,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM122732"],"award-info":[{"award-number":["P30GM122732"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R41TR002298"],"award-info":[{"award-number":["R41TR002298"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["P30GM122732"],"award-info":[{"award-number":["P30GM122732"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["R41TR002298"],"award-info":[{"award-number":["R41TR002298"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The musculoskeletal system (MSKS) is composed of specialized connective tissues including bone, muscle, cartilage, tendon, ligament, and their subtypes. The primary function of the MSKS is to provide protection, structure, mobility, and mechanical properties to the body. In the process of fulfilling these functions, the MSKS is subject to wear and tear during aging and after injury and requires subsequent repair. MSKS diseases are a growing burden due to the increasing population age. The World Health Organization estimates that 1.71 billon people suffer from MSKS diseases worldwide. MSKS diseases usually involve various dysfunctions in bones, muscles, and joints, which often result in pain, disability, and a decrease in quality of life. The most common MSKS diseases are osteoporosis (loss of bone), osteoarthritis (loss of cartilage), and sarcopenia (loss of skeletal muscle). Because of the disease burden and the need for treatment, regenerative drug therapies for MSKS disorders are increasingly in demand. However, the difficulty of effective drug delivery in the MSKS has become a bottleneck for developing MSKS therapeutics. The abundance of extracellular matrix and its small pore size in the MSKS present a formidable barrier to drug delivery. Differences of vascularity among various MSKS tissues pose complications for drug delivery. Novel strategies are necessary to achieve successful drug delivery in different tissues composing the MSKS. Those considerations include the route of administration, mechanics of surrounding fluids, and biomolecular interactions, such as the size and charge of the particles and targeting motifs. This review focuses on recent advances in challenges to deliver drugs to each tissue of the MSKS, current strategies of drug delivery, and future ideas of how to overcome drug delivery challenges in the MSKS.<\/jats:p>","DOI":"10.3390\/ph16070967","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T02:37:29Z","timestamp":1688697449000},"page":"967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Smart Strategies to Overcome Drug Delivery Challenges in the Musculoskeletal System"],"prefix":"10.3390","volume":"16","author":[{"given":"Brandon","family":"Vorrius","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology and Nanomedicine, Department of Orthopaedics, Alpert Medical School of Brown University\/Rhode Island Hospital, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qiao","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and Nanomedicine, Department of Orthopaedics, Alpert Medical School of Brown University\/Rhode Island Hospital, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ge","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and Nanomedicine, Department of Orthopaedics, Alpert Medical School of Brown University\/Rhode Island Hospital, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-5618","authenticated-orcid":false,"given":"Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology and Nanomedicine, Department of Orthopaedics, Alpert Medical School of Brown University\/Rhode Island Hospital, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/acs.biomac.7b01193","article-title":"Multivalent Presentation of Peptide Targeting Groups Alters Polymer Biodistribution to Target Tissues","volume":"19","author":"Newman","year":"2018","journal-title":"Biomacromolecules"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/jbmr.1777","article-title":"Periosteum, bone\u2019s \u201csmart\u201d bounding membrane, exhibits direction-dependent permeability","volume":"28","author":"Evans","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1038\/s41598-018-28228-w","article-title":"Knee Joint Tissues Effectively Separate Mixed Sized Molecules Delivered in a Single Bolus to the Heart","volume":"8","author":"Ngo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_4","first-page":"350","article-title":"Efficacy and safety of alendronic acid in the treatment of osteoporosis in children","volume":"39","year":"2015","journal-title":"Farm. Hosp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coph.2018.03.013","article-title":"Intra-articular drug delivery systems for joint diseases","volume":"40","author":"Rai","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.actbio.2019.01.043","article-title":"Recent advances in musculoskeletal local drug delivery","volume":"93","author":"Zhang","year":"2019","journal-title":"Acta Biomater."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2015.12.015","article-title":"Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice","volume":"498","author":"Pradal","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_8","first-page":"577","article-title":"Probing the tissue to subcellular level structure underlying bone\u2019s molecular sieving function","volume":"40","author":"Tami","year":"2003","journal-title":"Biorheology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10456-017-9541-1","article-title":"The role of vasculature in bone development, regeneration and proper systemic functioning","volume":"20","author":"Filipowska","year":"2017","journal-title":"Angiogenesis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5742\/MEAA.2014.92392","article-title":"Management of supraspinatus muscle tear by using mini approach","volume":"11","author":"Mustafa","year":"2014","journal-title":"Middle East. J. Age Ageing"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/abbi.1996.0397","article-title":"Contributions of fluid convection and electrical migration to transport in cartilage: Relevance to loading","volume":"333","author":"Garcia","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.abb.2013.04.011","article-title":"Solute transport across the articular surface of injured cartilage","volume":"535","author":"Chin","year":"2013","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrrheum.2016.210","article-title":"Cartilage-targeting drug delivery: Can electrostatic interactions help?","volume":"13","author":"Bajpayee","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1097\/GOX.0000000000002034","article-title":"Pedicled Peroneal Artery Perforator Flap for Knee Defect Reconstruction: Case Presentation and Literature Discussion","volume":"6","author":"Alshomer","year":"2018","journal-title":"Plast. Reconstr. Surg. Glob. Open."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.actbio.2017.08.032","article-title":"Tendon injury and repair\u2014A perspective on the basic mechanisms of tendon disease and future clinical therapy","volume":"63","author":"Snedeker","year":"2017","journal-title":"Acta Biomater."},{"key":"ref_16","first-page":"25","article-title":"[Sports Injuries and Illnesses of the German National Team during the 2016 Olympic Summer Games in Rio de Janeiro]","volume":"31","author":"Grim","year":"2017","journal-title":"Sportverletz. Sportschaden"},{"key":"ref_17","first-page":"5","article-title":"[Obstacles in wound healing]","volume":"67","author":"Huljev","year":"2013","journal-title":"Acta Med. Croatica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","article-title":"Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference\u2013based bone anabolic strategy","volume":"21","author":"Liang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbagen.2018.06.003","article-title":"Engineered exosomes: A new promise for the management of musculoskeletal diseases","volume":"1862","author":"Bellavia","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actbio.2016.07.041","article-title":"Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis","volume":"42","author":"Boccardo","year":"2016","journal-title":"Acta Biomater."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/ar.24186","article-title":"Mesenchymal Stem Cell (MSC)-Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine","volume":"303","author":"Yuan","year":"2020","journal-title":"Anat. Rec."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.nano.2014.05.013","article-title":"Small molecule delivery through nanofibrous scaffolds for musculoskeletal regenerative engineering","volume":"10","author":"Carbone","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nano.2016.08.015","article-title":"Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties","volume":"13","author":"Carbone","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/mabi.201500455","article-title":"Bioactive, Elastic, and Biodegradable Emulsion Electrospun DegraPol Tube Delivering PDGF-BB for Tendon Rupture Repair","volume":"16","author":"Evrova","year":"2016","journal-title":"Macromol. Biosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1021\/acsnano.7b05528","article-title":"The Effects of Biological Fluids on Colloidal Stability and siRNA Delivery of a pH-Responsive Micellar Nanoparticle Delivery System","volume":"12","author":"Malcolm","year":"2018","journal-title":"ACS Nano"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"629928","DOI":"10.3389\/fbioe.2021.629928","article-title":"Zoledronic Acid-Loaded Hybrid Hyaluronic Acid\/Polyethylene Glycol\/Nano-Hydroxyapatite Nanoparticle: Novel Fabrication and Safety Verification","volume":"9","author":"Xu","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111048","DOI":"10.1016\/j.msec.2020.111048","article-title":"Mechanical on-off gates for regulation of drug release in cutaneous or musculoskeletal tissue repairs","volume":"115","author":"Wei","year":"2020","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1559325820929555","DOI":"10.1177\/1559325820929555","article-title":"A Novel Fabrication of Dose-Dependent Injectable Curcumin Biocomposite Hydrogel System Anesthetic Delivery Method for Care and Management of Musculoskeletal Pain","volume":"18","author":"Jiang","year":"2020","journal-title":"Dose Response"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119591","DOI":"10.1016\/j.biomaterials.2019.119591","article-title":"Oral delivery of novel human IGF-1 bioencapsulated in lettuce cells promotes musculoskeletal cell proliferation, differentiation and diabetic fracture healing","volume":"233","author":"Park","year":"2020","journal-title":"Biomaterials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11095-016-2038-6","article-title":"Matrix Metalloproteinase Responsive Delivery of Myostatin Inhibitors","volume":"34","author":"Braun","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jbmr.2816","article-title":"Small Players Ruling the Hard Game: siRNA in Bone Regeneration","volume":"31","author":"Ghadakzadeh","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2015.04.022","article-title":"Targeted delivery as key for the success of small osteoinductive molecules","volume":"94","author":"Balmayor","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tibtech.2016.09.008","article-title":"Human-Based Biological and Biomimetic Autologous Therapies for Musculoskeletal Tissue Regeneration","volume":"35","author":"Padilla","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejpb.2018.02.023","article-title":"Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: A review","volume":"127","author":"Wang","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.7-6-481","article-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy","volume":"7","author":"Major","year":"2002","journal-title":"Oncologist"},{"key":"ref_36","first-page":"327","article-title":"Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy","volume":"44","author":"Adachi","year":"1998","journal-title":"Can. Fam. Physic."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: Results of FACTS -international","volume":"26","author":"Reid","year":"2006","journal-title":"Clin. Drug. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","article-title":"Targeted delivery to bone and mineral deposits using bisphosphonate ligands","volume":"99","author":"Cole","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/PPA.S46192","article-title":"A review of denosumab for the treatment of osteoporosis","volume":"8","author":"Miyazaki","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11914-010-0034-z","article-title":"Denosumab for the treatment of osteoporosis","volume":"8","author":"Iqbal","year":"2010","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00296-018-4106-1","article-title":"Denosumab in the treatment of glucocorticoid-induced osteoporosis","volume":"38","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/DDDT.S127568","article-title":"Profile of romosozumab and its potential in the management of osteoporosis","volume":"11","author":"Lim","year":"2017","journal-title":"Drug. Des. Devel Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","article-title":"Romosozumab for the treatment of osteoporosis","volume":"4","author":"McClung","year":"2018","journal-title":"Osteoporos. Sarcopenia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.copbio.2016.02.029","article-title":"Local and targeted drug delivery for bone regeneration","volume":"40","author":"Newman","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1021\/acsnano.7b05103","article-title":"Fracture-Targeted Delivery of \u03b2-Catenin Agonists via Peptide-Functionalized Nanoparticles Augments Fracture Healing","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/1381612820666140929095755","article-title":"Strategies for skeletal muscle targeting in drug discovery","volume":"21","author":"Ebner","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1002\/jps.22557","article-title":"Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2","volume":"100","author":"Diao","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6065\/apem.2016.21.2.99","article-title":"A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia","volume":"21","author":"Park","year":"2016","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10067-010-1486-3","article-title":"The role of zoledronic acid in the management of osteoporosis","volume":"29","author":"Maricic","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1995-7645(12)60118-7","article-title":"Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis","volume":"5","author":"Zhang","year":"2012","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1097\/MJT.0000000000000415","article-title":"Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Wang","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel","volume":"158","author":"Kumar","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biomaterials.2017.10.053","article-title":"Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis","volume":"154","author":"Yamashita","year":"2018","journal-title":"Biomaterials"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14712598.2017.1263614","article-title":"Denosumab: Targeting the RANKL pathway to treat rheumatoid arthritis","volume":"17","author":"Chiu","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"799575","DOI":"10.3389\/fimmu.2021.799575","article-title":"The Efficacy of Denosumab in Patients with Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14728222.2018.1502273","article-title":"Recent advances in drug delivery via the organic cation\/carnitine transporter 2 (OCTN2\/SLC22A5)","volume":"22","author":"Kou","year":"2018","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-11-0980","article-title":"Inhibition of OCTN2-mediated transport of carnitine by etoposide","volume":"11","author":"Hu","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/bj20031034","article-title":"Targeting of skeletal muscle in vitro using biotinylated immunoliposomes","volume":"377","author":"Schnyder","year":"2004","journal-title":"Biochem. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2014.63","article-title":"Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice","volume":"22","author":"Gao","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/hmg\/ddt003","article-title":"Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy","volume":"22","author":"Lawlor","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1021\/acs.molpharmaceut.8b01313","article-title":"Enhanced Delivery of Plasmid DNA to Skeletal Muscle Cells using a DLC8-Binding Peptide and ASSLNIA-Modified PAMAM Dendrimer","volume":"16","author":"Jativa","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtn.2017.12.004","article-title":"Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers","volume":"10","author":"Philippou","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1016\/j.actbio.2013.01.016","article-title":"Biomaterial-mediated delivery of degradative enzymes to improve meniscus integration and repair","volume":"9","author":"Qu","year":"2013","journal-title":"Acta Biomater."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.addr.2014.11.022","article-title":"The past, present and future in scaffold-based tendon treatments","volume":"84","author":"Lomas","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2011.08.020","article-title":"Ultrasound and microbubble-assisted gene delivery in Achilles tendons: Long lasting gene expression and restoration of fibromodulin KO phenotype","volume":"156","author":"Delalande","year":"2011","journal-title":"J. Control. Release"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:07:08Z","timestamp":1760126828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":66,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16070967"],"URL":"https:\/\/doi.org\/10.3390\/ph16070967","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}